SPDR S&P Biotech ETF logo

SPDR S&P Biotech ETF (SSGF)

Market Closed
7 Oct, 07:24
XHAM XHAM
88. 13
+0.17
+0.19%
- Market Cap
0.46% Div Yield
0 Volume
87.96
Previous Close
Day Range
88.13 88.13
Year Range
62.33 97.24
Want to track SSGF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SSGF closed yesterday higher at €88.13, an increase of 0.19% from Monday's close, completing a monthly increase of 15.64% or €11.92. Over the past 12 months, SSGF stock gained 1.56%.
SSGF pays dividends to its shareholders, with the most recent payment made on Sep 24, 2025. The next estimated payment will be in In 2 months on Dec 24, 2025 for a total of €0.02665.
SPDR S&P Biotech ETF has completed 1 stock splits, with the recent split occurring on Sep 11, 2015.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on ARCA (USD).

SSGF Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.

Zacks | 1 month ago
XBI: Surprise Exit Of A Tough Regulator At The FDA

XBI: Surprise Exit Of A Tough Regulator At The FDA

XBI has rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a tougher regulatory environment. Vinay Prasad was only appointed in May, but is now leaving the FDA, meaning there will again be a new Director of the Center for Biologics Evaluation and Research. Prasad's appointment caused XBI to drop in May, but the sector still continued on with its recovery.

Seekingalpha | 2 months ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Zacks | 3 months ago

SPDR S&P Biotech ETF Dividends

SPDR S&P Biotech ETF logo
XBI In 2 months
Estimated
Quarterly
$0.03 Per Share
SPDR S&P Biotech ETF logo
XBI 2 weeks ago
Paid
Quarterly
$0.03 Per Share
SPDR S&P Biotech ETF logo
XBI 9 months ago
Paid
Quarterly
$0 Per Share
SPDR S&P Biotech ETF logo
XBI 23 Sep 2024
Paid
Quarterly
$0.01 Per Share
SPDR S&P Biotech ETF logo
XBI 24 Jun 2024
Paid
Quarterly
$0.12 Per Share
SPDR S&P Biotech ETF logo
XBI 18 Dec 2023
Paid
Quarterly
$0.01 Per Share

SPDR S&P Biotech ETF Earnings

SSGF have yet to publish their earning reports.
SPDR S&P Biotech ETF logo
XBI In 2 months
Estimated
Quarterly
$0.03 Per Share
SPDR S&P Biotech ETF logo
XBI 2 weeks ago
Paid
Quarterly
$0.03 Per Share
SPDR S&P Biotech ETF logo
XBI 9 months ago
Paid
Quarterly
$0 Per Share
SPDR S&P Biotech ETF logo
XBI 23 Sep 2024
Paid
Quarterly
$0.01 Per Share
SPDR S&P Biotech ETF logo
XBI 24 Jun 2024
Paid
Quarterly
$0.12 Per Share
SPDR S&P Biotech ETF logo
XBI 18 Dec 2023
Paid
Quarterly
$0.01 Per Share
SSGF have yet to publish their earning reports.

SPDR S&P Biotech ETF (SSGF) FAQ

What is the stock price today?

The current price is €88.13.

On which exchange is it traded?

SPDR S&P Biotech ETF is listed on ARCA.

What is its stock symbol?

The ticker symbol is SSGF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.46%.

What is its market cap?

As of today, no market cap data is available.

Has SPDR S&P Biotech ETF ever had a stock split?

SPDR S&P Biotech ETF had 1 splits and the recent split was on Sep 11, 2015.

SPDR S&P Biotech ETF Profile

XHAM Exchange
US Country

Overview

The provided company is a financial entity that focuses on mirroring the performance of the S&P Biotechnology Select Industry Index. By employing a sampling strategy, the fund aims to invest predominantly, if not entirely, in the components that make up the index. This index is a representation of the biotechnology segment of the S&P Total Market Index (S&P TMI), encompassing companies within the biotechnology industry. The strategy includes investing at least 80% of its total assets in the securities that form part of the index, ensuring a strong alignment with the biotechnology sector's market movements.

Products and Services

  • Biotechnology Industry Index Fund

    This product is designed for investors seeking exposure to the biotechnology sector. The fund tracks the S&P Biotechnology Select Industry Index, which is a subset of the larger S&P Total Market Index (S&P TMI) focused specifically on the biotechnology industry. By putting a significant portion of its assets—substantially all, but at a minimum, 80%—into the securities that compose the index, the fund offers a direct pathway for investment in a diversified portfolio of biotechnology companies. The sampling strategy employed aims to replicate the index's performance, making it an attractive option for those looking to invest in the biotechnology industry through a mechanism that mirrors its market dynamics closely.

Contact Information

Address: -
Phone: NA